Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.
A James Island pharmacist is looking to the future of pain management thanks to the Food and Drug Administration approving a new treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback